MET and neoplasm: More specifically, we unequivocally demonstrate that OMO-1 treatment: (1) reduces malignant progression and provides additional antitumor effects to cisplatin in a model that is not c-MET oncogene addicted; (2) induces immunostimulatory and tumor suppressing expression profiles, further characterized by a favorable TME with significantly reduced numbers of TAMs in combination with cisplatin; and (3) reduces hypoxia, increases cisplatin delivery, and subsequent cell death in primary tumors potentially through vessel normalization.